Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPE with or without Ruxolitinib in COVID-19 CRS
NCT04374149Phase 2Completed
- Sponsor
- Prisma Health
- Start
- Apr 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in cytokine release syndrome (CRS), sponsored by Prisma Health. Started Apr 2020; status: completed.
02
Drugs
03
Conditions
cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT04374149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04374149.